Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.49 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422277 | 0.80 | CYP24A1 (0.53) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL4602048 | 0.74 | DDB1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL13039619 | 0.74 | DRD2 (0.60) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL630841 | 0.73 | ACHE (0.58) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7271049 | 0.73 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7147602 | 0.72 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL2440274 | 0.72 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL22867686 | 0.72 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL5753017 | 0.72 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL3587277 | 0.72 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | LEONARD DANIELE MARIE (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | WARNER-LAMBERT COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1276724-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001079179-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | NRAS, HRAS, FNTB | CYP24A1 889/4885CYP27A1 340/4885CYP26A1 406/4885 |
| US-20040063770-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | CYP24A1 557/4885CYP27A1 18/4885CYP26A1 249/4885 |
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | CYP24A1 557/4885CYP27A1 18/4885CYP26A1 249/4885 |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | CYP24A1 771/4885CYP27A1 112/4885CYP26A1 172/4885 |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | NRAS, FNTA, CYP46A1 | CYP24A1 166/4885CYP27A1 105/4885CYP26A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.